Skip Navigation

Annals of Oncology 2006 17(Supplement 5):v148-v152; doi:10.1093/annonc/mdj971
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cascinu, S.
Right arrow Articles by Scartozzi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cascinu, S.
Right arrow Articles by Scartozzi, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

symposium article

New target therapies in advanced pancreatic cancer

S. Cascinu*, L. Verdecchia, N. Valeri, R. Berardi and M. Scartozzi

Clinica di Oncologia Medica, Università Politecnica delle Marche; Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Umberto I, Lancisi, Salesi, Ancona, Italy

* Correspondence to: Prof. S. Cascinu, Clinica di Oncologia Medica, Università Politecnica delle Marche; Ospedali Riuniti di Ancona, Umberto I, Lancisi, Salesi; via Conca 71, 60020 Ancona. Italy. Tel: +71 5964169; Fax: +71 5964192; E-mail: cascinu{at}yahoo.com

The recent elucidation both of the mechanisms involved in pancreatic cancer carcinogenesis and the related molecular events, has led to several distinct therapeutic advances, including many novel target agents, such as monoclonal antibodies against EGFR, EGFR-tyrosine kinase inhibitors, monoclonal antibody against VEGF, farnesyl transferase inhibitors, matrix metalloproteinase inhibitors, COX 2 inhibitors, and the development of gene therapy to target pancreatic cancer. This review highlights recent findings in the treatment of pancreatic cancer by using these novel therapeutic approaches.

Key words: pancreatic cancer, EGFR inhibitor, farnesyl transferase inhibitor, COX-2 inhibitor


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.